Literature DB >> 23820056

HDAC dependent transcriptional repression of Bmp-7 potentiates TGF-β mediated renal fibrosis in obstructive uropathy.

Scott R Manson1, Joseph B Song1, Keith A Hruska1, Paul F Austin2.   

Abstract

PURPOSE: Recombinant BMP-7 inhibits the pathogenesis of renal injury in response to various stimuli. However, little is known about the molecular regulation of endogenous BMP-7 and its renal protective functions. We examined transcriptional regulation of Bmp-7 and its role in the pathogenesis of renal injury resulting from urinary tract dysfunction.
MATERIALS AND METHODS: Obstruction induced renal injury was modeled in vivo in mice by unilateral ureteral obstruction and in vitro in primary kidney cells by treatment with transforming growth factor-β, a profibrotic cytokine that is increased in the obstructed kidney.
RESULTS: Unilateral ureteral obstruction resulted in the loss of BMP-7 expression in conjunction with histone deacetylation and transcriptional repression of the Bmp-7 promoter. The histone deacetylase inhibitor trichostatin A stimulated Bmp-7 expression in primary kidney cells. Trichostatin A also inhibited the expression of transforming growth factor-β dependent profibrotic genes in a manner that depended on BMP receptor signaling. These findings extended to the obstructed kidney in vivo, in which trichostatin A treatment restored the expression of Bmp-7 along with BMP-7 mediated suppression of transforming growth factor-β dependent signaling pathways. Finally, trichostatin A stimulated activation of the BMP-7 pathway the ameliorated obstruction induced renal injury by preventing disruption of the renal architecture and the development of renal fibrosis.
CONCLUSIONS: These findings show that histone deacetylase dependent repression of Bmp-7 transcription is a critical event during the pathogenesis of renal injury in obstructive uropathy. Accordingly, treatment with histone deacetylase inhibitors represents a potentially effective strategy to restore BMP-7 expression and its renal protective functions during treatment of obstructive uropathy.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMP-7; COLIα1; ELISA; GAPDH; HDAC; IMCD; PCR; RT-PCR; SMA- and MAD-related protein; SMAD; TGF-β; TSA; UUO; bone morphogenetic protein 7; bone morphogenic protein 7; enzyme-linked immunosorbent assay; fibrosis; glyceraldehyde-3-phosphate dehydrogenase; histone deacetylase; histone deacetylase inhibitors; inner medullary collecting duct; kidney; polymerase chain reaction; reverse transcriptase-PCR; transforming growth factor-β; trichostatin A; type I collagen, α1 chain; unilateral ureteral obstruction; ureteral obstruction; α-SMA; α-smooth muscle actin

Mesh:

Substances:

Year:  2013        PMID: 23820056      PMCID: PMC4084877          DOI: 10.1016/j.juro.2013.06.110

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

2.  Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction.

Authors:  K A Hruska; G Guo; M Wozniak; D Martin; S Miller; H Liapis; K Loveday; S Klahr; T K Sampath; J Morrissey
Journal:  Am J Physiol Renal Physiol       Date:  2000-07

3.  Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

Authors:  Nilamadhab Mishra; Christopher M Reilly; Doris R Brown; Phil Ruiz; Gary S Gilkeson
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

4.  Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy.

Authors:  Shi-Nong Wang; Janine Lapage; Raimund Hirschberg
Journal:  J Am Soc Nephrol       Date:  2001-11       Impact factor: 10.121

5.  Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models.

Authors:  Michael Zeisberg; Cindy Bottiglio; Navin Kumar; Yohei Maeshima; Frank Strutz; Gerhard A Müller; Raghu Kalluri
Journal:  Am J Physiol Renal Physiol       Date:  2003-08-12

6.  Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.

Authors:  Song Wang; Qing Chen; Theodore C Simon; Frank Strebeck; Lala Chaudhary; Jeremiah Morrissey; Helen Liapis; Saulo Klahr; Keith A Hruska
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

Review 7.  Obstructive uropathy: an important cause of chronic renal failure in children.

Authors:  Karl S Roth; Harry P Koo; Stephanie E Spottswood; James C M Chan
Journal:  Clin Pediatr (Phila)       Date:  2002-06       Impact factor: 1.168

8.  Regulation of the alpha 1(I) collagen promoter via a transforming growth factor-beta activation element.

Authors:  J D Ritzenthaler; R H Goldstein; A Fine; B D Smith
Journal:  J Biol Chem       Date:  1993-06-25       Impact factor: 5.157

9.  BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.

Authors:  Michael Zeisberg; Jun-ichi Hanai; Hikaru Sugimoto; Tadanori Mammoto; David Charytan; Frank Strutz; Raghu Kalluri
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.

Authors:  L Sanderson; G W Taylor; E O Aboagye; J P Alao; J R Latigo; R C Coombes; D M Vigushin
Journal:  Drug Metab Dispos       Date:  2004-07-21       Impact factor: 3.922

View more
  22 in total

Review 1.  Potential approaches to reverse or repair renal fibrosis.

Authors:  Desiree Tampe; Michael Zeisberg
Journal:  Nat Rev Nephrol       Date:  2014-02-11       Impact factor: 28.314

2.  Deacetylation of S6 kinase promotes high glucose-induced glomerular mesangial cell hypertrophy and matrix protein accumulation.

Authors:  Falguni Das; Soumya Maity; Nandini Ghosh-Choudhury; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2019-04-26       Impact factor: 5.157

3.  Dynamic changes in histone deacetylases following kidney ischemia-reperfusion injury are critical for promoting proximal tubule proliferation.

Authors:  Kelly A Hyndman; Malgorzata Kasztan; Luciano D Mendoza; Sureena Monteiro-Pai
Journal:  Am J Physiol Renal Physiol       Date:  2019-02-27

4.  Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses.

Authors:  J Ren; X Liao; M D Vieson; M Chen; R Scott; J Kazmierczak; X M Luo; C M Reilly
Journal:  Clin Exp Immunol       Date:  2017-10-16       Impact factor: 4.330

5.  SAHA Suppresses Peritoneal Fibrosis in Mice.

Authors:  Kumiko Io; Tomoya Nishino; Yoko Obata; Mineaki Kitamura; Takehiko Koji; Shigeru Kohno
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

6.  Histone acetylation regulates prostate ductal morphogenesis through a bone morphogenetic protein-dependent mechanism.

Authors:  Kimberly P Keil; Helene M Altmann; Lisa L Abler; Laura L Hernandez; Chad M Vezina
Journal:  Dev Dyn       Date:  2015-09-02       Impact factor: 3.780

Review 7.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

Review 8.  Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis.

Authors:  Ling Nie; Yong Liu; Bo Zhang; Jinghong Zhao
Journal:  Kidney Dis (Basel)       Date:  2020-03-26

Review 9.  Treatment of chronic kidney diseases with histone deacetylase inhibitors.

Authors:  Na Liu; Shougang Zhuang
Journal:  Front Physiol       Date:  2015-04-28       Impact factor: 4.566

10.  Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis.

Authors:  Fang Chen; Qi Gao; Ai Wei; Xingren Chen; Yujun Shi; Hongwei Wang; Wangsen Cao
Journal:  Cell Death Differ       Date:  2020-10-06       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.